HIV patients respond well to Gilead's 4-drug combo in study

09/19/2011 | Bloomberg

Quad, an investigational four-drug cocktail by Gilead Sciences, achieved a 90% response rate among HIV patients in a Phase III trial, compared with 87% for those given Atripla, an approved treatment combining Gilead's two-in-one pill Truvada and Bristol-Myers Squibb's Sustiva. Gilead aims to file by year-end for FDA approval of Quad, said chief scientific officer Norbert Bischofberger.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations